https://clinicaltrials.gov/ct2/show/NCT02518139?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: TD-4208; Drug: Tiotropium Sponsor : Theravance Biopharma Completed NCT02518139 Fri, 07 Aug 2015 12:00:00 EDT
Theravance Biopharma
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
https://clinicaltrials.gov/ct2/show/NCT02459080?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F17%2F2018&lupd_d=14&sort=nwst Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Condition : Chronic Obstructive Pulmonary Disease (COPD) Interventions : Drug: TD-4208; Drug: Placebo Sponsor : Theravance Biopharma Completed NCT02459080 Mon, 01 Jun 2015 12:00:00 EDT
Theravance Biopharma and Mylan Receive FDA Approval for YUPELRI™ (revefenacin) in Adults with Chronic Obstructive Pulmonary Disease
https://www.prnewswire.com/news-releases/theravance-biopharma-and-mylan-receive-fda-approval-for-yupelri-revefenacin-in-adults-with-chronic-obstructive-pulmonary-disease-300747672.html
